Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 18, 2022
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
[ Mon, Apr 18th 2022
] - WOPRAI
Colin Bristow Maintained (CCCC) at Strong Buy with Decreased Target to $26 on, Apr 18th, 2022
Colin Bristow of UBS, Maintained "C4 Therapeutics, Inc." (CCCC) at Strong Buy with Decreased Target from $64 to $26 on, Apr 18th, 2022.
Colin has made no other calls on CCCC in the last 4 months.
There are 3 other peers that have a rating on CCCC. Out of the 3 peers that are also analyzing CCCC, 1 agrees with Colin's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Derek Archila of "Wells Fargo" Initiated at Hold and Held Target at $25 on, Thursday, February 10th, 2022
These are the ratings of the 2 analyists that currently disagree with Colin
- Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $20 on, Monday, April 11th, 2022
- Eric Joseph of "JP Morgan" Initiated at Buy and Held Target at $43 on, Thursday, March 10th, 2022
